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Despite major advances in molecular biol-ogy and targeted therapy of leukemia, cur-rent treatment strategies induce adverse side 
effects and fail to achieve and maintain remission in 
many patients. In acute myeloid leukemia (AML), the 
most deadly form of leukemia,1,2 the majority of adult 
patients younger than 60 years achieve a complete re-
mission following consolidation therapy. However, only 
approximately 30% to 40% maintain durable remission.3 
Furthermore, the complete remission rate and duration 
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BACkgROunD AnD OBjECtIvEs: there is an urgent need for the development of leukemia-targeted im-
munotherapeutic approaches using defined leukemia-associated antigens that are preferentially expressed by 
most leukemia subtypes and absent or minimally expressed in vital tissues. m-phase phosphoprotein 11 protein 
(mpp11) is extensively overexpressed in leukemic cells and therefore is considered an attractive target for leu-
kemia t cell therapy. We sought to identify potential cd8+ cytotoxic t lymphocytes that specifically recognised 
peptides derived from the mpp11 antigen. 
MAtERIALs AnD MEthODs: a computer-based epitope prediction program sYfpeithi, was used to predict 
peptides from the mpp11 protein that bind to the most common hla- a*0201 molecule. peptide binding ca-
pacity to the hla-a*0201 molecule was measured using the t2 tap-deficient, hla-a*0201-positive cell line. 
dendritic cells were pulsed with peptides and then used to generate cd8+ cytotoxic t lymphocytes (ctl). the 
cml leukemic cell line K562-a2.1 naturally expressing the mpp11 antigen and engineered to express the hla-
a*0201 molecule was used as the target cell. 
REsuLts: We have identified a potential hla-a*0201 binding epitope (stlcQVepV) named mpp-4 derived 
from the mpp11 protein which was used to generate a ctl line. interestingly, this ctl line specifically rec-
ognized peptide-loaded target cells in both elispot and cytotoxic assays. importantly, this ctl line exerted a 
cytotoxic effect towards the cml leukemic cell line K562-a2.1. 
COnCLusIOn: this is the first study to describe a novel epitope derived from the mpp11 antigen that has been 
recognized by human cd8+ ctl. 
attained by older AML patients is less, with an overall 
survival rate of 20% to 40%.3 Therefore, there is an ur-
gent need for the development of leukemia-targeted im-
munotherapy designed to eliminate residual leukemic 
cells thus enhancing the graft-versus-leukemia (GVL) 
effect observed after allogeneic hematopoietic stem cell 
transplantation (HSCT) and/or prolonging a complete 
remission achieved by chemotherapy.4,5 
Leukemia cells express unique antigens or overex-
press normal cellular antigens.6,7 The overexpressed 
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normal antigens constitute attractive targets for the 
development of leukemia immunotherapy.6 Among 
this group of antigens are the M-phase phosphopro-
tein 11 (MPP11) proteins. MPP11 was discovered by 
Matsumoto-Taniura et al8,9 using an MPM2 mono-
clonal antibody, which recognizes several important 
mitosis phosphoproteins found to be present during 
mitosis.8-10 Recently, it has been reported that MPP11 
functions as a ribosome-associated molecular chaper-
one.11,12 MPP11 maps to the region of chromosome 
7q22-31.1, which is a critical common position in hu-
man cancer.10,13 MPP11 has been detected by serologi-
cal analysis of cDNA expression libraries (SEREX) 
in solid tumours and hematological malignancies 
including melanoma, breast, renal cell carcinoma, 
small cell lung cancer and leukemia.14,15 The humoral 
immune responses to MPP11 have been detected in 
patients with acute (AML) and chronic myeloid leu-
kemia (CML), but not in healthy donors or patients 
with autoimmune diseases.15 Moreover, this protein 
has been found to be expressed extensively in AML 
and CML patients as compared to normal controls.15-
18 Immunohistochemical staining of primary tumor 
sections and Western blot analysis of head and neck 
squamous cell cancer (HNSCC) cell lines revealed 
tumor-specific overexpression of MPP11 protein.13,15 
Additionally, fluorescence in situ hybridization analy-
sis carried out on HNSCC cell lines showed an in-
crease in the copy number of MPP11 along with chro-
mosome 7 suggesting an oncogenic role for MPP11.13 
The specific overexpression of MPP11 by tumor tis-
sues (with the exception of very low expression in tes-
tis, kidney, and lung) makes it an attractive target for 
cancer immunotherapies.15,17 
We sought to identify potential CD8+ cytotoxic T 
lymphocyte (CTL) epitopes in the leukemia-associ-
ated MPP11 antigen that bind to the most common 
HLA-A*0201 molecule and provoke specific CTL re-
sponses. Although various antigenic epitopes derived 
from leukemia antigens have been identified, progress 
in targeting specific immunotherapeutic approaches 
depends on the recognition of a wider range of leuke-
mia antigens. This would allow the use of these pep-
tides in leukemia immunotherapy by either expanding 
ex vivo tumor-reactive specific CTLs for adoptive T 
cell therapy or actively inducing leukemia antigen-spe-
cific T-cell immunity in vivo by vaccinating patients 
with well-defined leukemia-associated antigens. 
MAtERIALs AnD MEthODs 
Leukocyte-rich buffy coats not older than eight hours 
were obtained from healthy volunteers from the blood 
bank. All samples were obtained with informed con-
sent at King Faisal Specialist Hospital and Research 
Centre (KFSHRC). Peripheral blood mononuclear 
cells (PBMCs) from healthy donors were isolated from 
heparinized blood by density gradient centrifugation 
over Ficoll-Paque PLUS (Amersham Biosciences) ac-
cording to the manufacturers’ instructions. PBMCs 
were suspended in 90% Fetal Calf Serum (FCS) + 
10% dimethyl sulfoxide (DMSO), aliquoted and cryo-
preserved in liquid nitrogen until further processing. 
The HLA typing of these samples was carried out at 
the routine immunopathology laboratory. 
T lymphocyte epitope prediction and peptide syn-
thesis 
The SYFPEITHI prediction algorithm is a data-
base comprising more than 4500 peptide sequences 
known to bind class I and class II MHC molecules. 
The scoring system of the SYFPEITHI program is 
based on the presence of certain amino acids in certain 
positions along the MHC-binding groove.19 Peptides 
qualified as positive if the score ranked ≥22. The 
amino acid sequences of MPP11 were entered into 
the specified program and candidate epitopes were se-
lected based on their predicted ability to bind to the 
HLA- A*0201 molecule. Four 9-mer peptides derived 
from MPP11 were selected as potential epitopes for 
the generation of CTL responses. The four peptides 
were: MPP-1N=MMP11-421-429 (QLLIKAVNL), 
MPP-2=MP11-419-427 (DLQLLIKAV), MPP-
3=MPP11-313-321 (AIMLLLPSA), and MPP-
4=MPP11-437-445 (STLCQVEPV). In addition 
to the predicted peptides, we modified the sequence 
of the first predicted peptide derived from MPP11 by 
introducing a Y at its N-terminus (wild type MPP-
1N= QLLIKAVNL, analog MPP-1Y=MPP11-
1Y(YLLIKAVNL) according to our recent study.20 
This approach enhanced both the binding and the 
immunogenicity of the modified peptide. The amino 
acid sequences of the nonameric peptides with a pu-
rity of ≥90% were synthesized and purified by Alta 
Bioscience, Birmingham, UK. 
T2 binding assay 
Peptide binding capacity to the HLA-A*0201 mol-
ecule was measured using the TAP-deficient, HLA-
A*0201-positive cells as described previously.21 
Briefly, T2 cells were washed three times, suspended 
at 106 cells/mL and incubated for 18 hours at 37ºC 
in serum-free medium containing 30 µM of each pep-
tide and 1 mg/mL b2-microglobulin (Sigma). Cells 
were then washed twice with cold FACS buffer (phos-
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phate buffered saline containing 2% FCS). Purified 
rabbit IgG (Sigma) was added to the cell suspension 
and incubated for 15 minutes on ice in order to block 
the FC receptors. FITC-conjugated mouse anti-
HLA-A2 antibody was added to the cell suspension 
(1 µg/106 cells), with a control sample labelled with 
isotype-matched monoclonal antibody and incubated 
for 30 min at 4ºC in the dark. The cells were washed 
twice with cold FACS buffer, and fixed with 300 µL 
of PBS/4% paraformaldehyde. The level of HLA-
A2 expression was analyzed using fluorescence-acti-
vated cell sorter (FACS) scan (Becton & Dickinson, 
Immunocytometry Systems, CA, USA). HLA-A2 
expression was quantified as fluorescence index (FI) 
according to the following formula: fluorescence index 
= (mean fluorescence intensity with peptide-mean 
fluorescence intensity without peptide)/mean fluores-
cence intensity without peptide. All T2 binding assays 
were carried out in duplicate. 
Cell lines 
The mutant TAP-deficient cell line T2 (ATCC num-
ber CRL-1992) and the HLA-class I and II negative 
human CML cell line K-562 (ATCC number CCL-
243) were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA). K-562 
cells transfected with the HLA-A*0201 gene22 were 
kindly provided by Dr. Wolfgang Herr (University 
of Mainz, Germany). The T2 and K562 cells were 
maintained in complete medium (CM) consisting of 
RPMI 1640 medium (Sigma, MO, USA) supple-
mented with 10% FCS (Cambrex Bio Science, MD, 
USA), 2 mM L-glutamine, 100 IU/mL penicillin and 
100 mg/mL streptomycin (Sigma). K562/ A*0201 
were cultured in CM containing 0.5 mg/mL geneticin 
(G418, Sigma). B-lymphoblastoid cell lines (LCLs) 
were established from normal donors by transforma-
tion of B cells using Epstein-Barr virus (EBV) accord-
ing to a standard technique.23 Briefly, PBMCs (107 
cells) were incubated with the virus (EBV virus stock, 
B95.8) for an hour at 37ºC. The cells were cultured in 
CM containing 1µg/mL PHA (PHA-P, Sigma) and 
0.1 ug/mL cyclosporin A, and established LCLs lines 
were used after 3-4 weeks of culture. 
Generation of DC2d dendritic cells (Fast-DC) 
Monocytes (CD14+ cells) were isolated from PBMCs 
of healthy HLA-A*0201 positive donors by plastic 
adherence. PBMCs were cultured at 5×106 cells/mL/
well of a 6-well plate (Sigma) in X-vivo 15 medium 
(DC-medium), and allowed to adhere in a 5% CO2 
incubator at 37ºC for 90-min. Non-adherent cells 
and media were removed and fresh DC-medium was 
added to the cells. After a second incubation period, 
non-adherent cells and media were removed and the 
adherent cells were washed carefully with pre-warmed 
medium. The DC2d were generated according to pre-
viously published protocols24,25 with minor modifica-
tions. Briefly, DC-medium supplemented with 100 
ng/mL rhGM-CSF and 50 ng/mL rhIL-4 (R&D 
Systems) was added to monocytes cultured in 6-well 
plates. Maturation cytokines, 10 ng/mL rhTNFa, 10 
ng/mL rhIL-1b, 10 ng/mL rhIL-6 (R&D Systems) 
and 1 mM PGE2 (Sigma), were added to the cultures 
on the next day. Cultures were incubated for an addi-
tional day before mature DC2d were harvested. 
Generation of anti-peptide specific CD8+ T lympho-
cytes 
CD8+ T lymphocytes were negatively separated from 
PBMCS obtained from healthy HLA-A*0201 posi-
tive donors using MACS CD8+ T Cell Isolation Kit 
II (Miltenyi Biotec) according to the manufacturer’s 
protocols. Some of the CD8+ T lymphocytes lines 
were generated using a protocol adapted from previ-
ous studies.21,26 Briefly, T2 cells were washed three 
times in serum-free medium and incubated with each 
peptide at concentrations of 50 µM/mL and 1 µg/mL 
b2-microglobulin at 37 °C, 5% CO2 for 2 hours. The 
peptide-pulsed T2 cells were then X-irradiated (7500 
rads), washed and added to freshly purified CD8+ T 
lymphocytes (T lymphocytes:T2 ratio of 5:1). After 
7-10 days of stimulation, the second stimulation 
was performed and on the following day, 20 IU/mL 
of rhIL-2 (R&D Systems) was added. The cultured 
T lymphocytes were maintained by re-stimulations 
with peptide-pulsed T2 cells. After the third in vi-
tro stimulation, the generated T lymphocytes were 
tested for their specificity and cytotoxic activity using 
enzyme-linked immunospot assay (ELISPOT) and 
chromium release assays. DC2d-loaded peptides were 
also used to in vitro prime some of the purified CD8+ 
T lymphocytes. Briefly, mature DC2d cells were har-
vested, washed in serum-free medium and incubated 
with the peptides at concentration of 50 µM/mL and 
5 µg/mL b2-microglobulin for 2 hours at 37°C, 5% 
CO2. The peptide loaded DCs were then X-irradiated 
(2500 rads), washed once and added to the CD8+ T 
lymphocytes at 20:1 to 5:1 T lymphocytes: DCs ratio. 
rhIL-7 (20 ng/mL) and rhIL-12 (100 pg/mL) (R&D 
Systems) were added to each culture. The cells were 
incubated in 2 mL T lymphocyte culture medium in 
24-well plates. After 7-10 days, T lymphocytes were 
harvested, washed and re-stimulated with peptide 
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loaded DC2d as previously described and rhIL-2 (20 
IU/mL) was added the following day. The cultured 
T lymphocytes were maintained by re-stimulation 
with autologous peptide-loaded adherent monocytes 
and feeding with rhIL-2 the next day. T lymphocytes 
lines against the different peptides were generated. 
Responder T lymphocytes were tested for their pep-
tide specificity and cytotoxic activity using enzyme-
linked immunospot assay (ELISPOT) and chromium 
release assay against different targets. 
Generation of T lymphocyte clones 
T lymphocytes lines were cloned by limiting dilution 
as described before25,27 with minor modifications. T 
lymphocytes were seeded at 1, 2 and 5 cells/well/200 µL 
T lymphocytes culture medium in 96-well U-bottomed 
plates. Allogeneic PBMCs were X-irradiated (2500 
rads) and used as a feeder layer (25×103 cells/well). T2 
cells were incubated separately in X-Vivo 15 medium 
(5×106 cells/mL) with 5 µg/mL b2-microglobulin and 
50 µM/mL of MPP11 peptides for 2 hours at 37ºC. 
T2 cells were then irradiated (7500 rads), washed once 
and used for T lymphocytes stimulation (50×103 cells/
well) in the presence of 130 IU/mL of rhIL-2.5ng/mL 
rhIL15 (R&D Systems), and 30ng/mL OKT3 (R&D 
Systems), were also added to the wells. The plates were 
incubated for 2-4 weeks. Cultures were re-fed with 
fresh medium containing rhIL-2 (130 IU/mL) every 
3-4 days. Wells with positive signs of growth were se-
lected for expansion. Growing clones were transferred 
to 96-well flat-bottomed plates, and each clone was 
stimulated with X-irradiated peptide-pulsed T2 cells. 
The activation cycle was repeated after 7-10 days of cul-
ture at T lymphocyte: T2 ratios of 20:1 to 5:1. Clones 
were screened for their lytic activity against T2-pulsed 
with or without peptide using chromium release assay. 
Cytotoxicity assay (chromium release assay) 
Cytotoxicity assays were performed 5 days post in vi-
tro stimulation. Target cells were removed from culture, 
washed in RPMI1640 serum-free medium, re-sus-
pended in a minimal volume (± 50 µL) of RPMI1640 
and incubated with 51Cr (100 µCi) per target for 90 
min. Target cells labelled with peptide were concur-
rently incubated with the appropriate peptide at 50 
µM/mL. The cells were then washed and placed in 
96 V-bottomed wells at 103 cells/100 µL/well. The ef-
fector T cells were washed, and added in triplicate at 
varying quantities to the target cells, to give varying ef-
fector to target ratios (E:T ratios) in a final volume of 
200 µL/well. The plates were spun for 5 min (300 g) 
and incubated for 4 hours at 37ºC and 5% CO2 before 
100 µL supernatants were removed and transferred to 
1450 Microbeta Plus Wallac plates (Wallac, Turku, 
Finland). 150 µL scintillation fluids, Optiphase HiSafe 
2 (Wallac), were added to each well and the plates were 
heat-sealed using a Microsealer system (Wallac). 
Chromium release was assessed by a liquid scintilla-
tion counter (Wallac). Target cells were also incubated 
with 0.2% Tween 20 or medium alone to assess the 
maximum and minimum (spontaneous) release of the 
chromium respectively. Spontaneous release was never 
exceeded 20% of the maximum release. The percentage 
of specific lysis was calculated as: % specific lysis = (ex-
perimental release–spontaneous release)/(maximal re-
lease–spontaneous release)×100. In some of the exper-
iments 10 µg/mL anti-class I ABC blocking antibody 
(clone: W6/32, AbD Serotec) was added to target cells 
before T lymphocytes addition. 
Enzyme-linked immunospot assay (ELISPOT) 
ELISPOT assay was performed using IFN-_, gran-
zyme B, and perforin kits (Mabtech, Mariemont, OH) 
according to the manufacturer’s protocols. 5×103 to 
5×104 T lymphocytes/well and 2×104 to 105 cells/well 
of different stimulators were seeded in Multiscreen 
96-well plates (Millipore, MA) pre-coated overnight 
(4ºC) with catching-antibody. The plates were then 
blocked with T lymphocytes culture medium. After 40 
hours incubation (37ºC, 5% CO2), cells were removed 
and after washing, biotinylated monoclonal antibodies 
specific for IFN-γ, granzyme B, or perforin were added 
and incubated for 3 hours at room temperature (RT). 
After washing, Streptavidin-alkaline phosphatase28 
or Streptavidin-horseradish peroxidase (HRP) were 
added to each well and incubated at RT for 2 hours. 
After washing, the appropriate substrate (BCIP/NBT 
in case of ALP and AEC in case of HRP) was added to 
each well and incubated at RT until color developed ac-
cording to the manufacturer’s instructions. Spots were 
counted using an automated ELISPOT reader (AID, 
Strasberg, Germany). Antigen-specific T lymphocytes 
frequencies were considered to be significantly higher 
if they were at least two-fold higher than in the control 
wells. 
REsuLts 
Selection of potential CTL epitopes derived from the 
MPP11 protein 
The amino acid sequences of MPP11 were entered into 
the computer program and potential candidate epitopes 
were selected, synthesized and tested for their capacity 
to bind to the HLA-A*0201 molecule and/or generate 
cytotoxic T lymphocytes responses. We selected four 
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native peptides derived from MPP11 protein using the 
Syfpeithi server available at www.syfpeithi.de. These 
peptides showed high theoretical binding affinity to the 
HLA-A*0201 molecule with binding scores ranging 
from 22 to 25. In addition to the predicted peptides, 
we have carried out tyrosine amino acid substitution in 
the P1 position of the first predicted epitope MPP-1Y 
(QLLIKAVNL). The binding score of the modified 
epitope, MPP-1Y (YLLIKAVNL), was enhanced from 
25 to 27 as assessed by the Syfpeithi program. The se-
quences of the peptides as well as their binding scores 
are presented in Table 1. 
We used the standard T2 binding assay to evaluate 
the ability of MPP11 candidate peptides to bind and 
stabilize the HLA-A*0201 molecule using the well-
characterized A2-binding peptides WT1-187 as a posi-
tive control (WT1 derived peptide known to effectively 
bind to the HLA-A*0201 molecule.20,29 The human 
processing-defective T2 cell line express empty HLA 
class I molecules. The binding assay is based on the sta-
bilization of HLA class I molecules on the cell surface 
by the addition of peptides exogenously. The T2 cells 
are incubated with peptides overnight and if the pep-
tide binds to the HLA-A*0201, the surface expression 
will be stabilized and there will be an upregulation of 
this molecule. Changes in its expression were assessed 
by staining HLA-A*0201 and quantifying the fluores-
cence intensity by flow cytometry analysis. The peptides 
are assumed to bind if their fluorescence ratio is greater 
than 1. All T2 binding assays were done in duplicate. 
As shown in Figure 1, the MPP-3 and MPP-4 peptides 
(Fluorescence Index [FI] =1.1 and 2.5 respectively) 
stably bind to the HLA*A-0201 molecule. The affinity 
of the MPP-4 peptide to the molecule was comparable 
with that observed for the positive control WT1-187 
epitope (FI=2.6). Because of their high binding affini-
ties, we selected MPP-3 and MPP-4 peptides for the 
generation of peptide-specific T lymphocytes lines. On 
the other hand, the peptides MPP-1N, MPP1-Y, and 
MPP-2 were excluded from testing for immunogenicity 
since they did not show any binding or only very weak 
binding to the HLA-A*0201 molecule. 
Generation of MPP11-specific T lymphocytes lines 
We tested the ability of the MPP11-derived peptides 
to induce specific cytotoxic T lymphocytes (CTLs). 
We used PBMCs obtained from four different HLA-
A*0201 positive healthy volunteers to generate CTLs 
specific to the selected peptides. The four donors were 
designated as BC-21, BC-32, BC-37 and BC-41. 
PBMCs from each donor were used as the source of 
the responder cells and antigen presenting cells. The 
responder cells were CD8+ T cells purified by MACS 
negative selection and stimulated in vitro with antigen 
presenting cells loaded with peptide for 7-10 days. 
Initially, we used T2 cells pulsed with peptides to prime 
and activate T lymphocytes raised against MPP11-de-
rived peptides. However, we did not observe any specific 
CD8+ T lymphocyte responses to any of the peptides 
tested including the WT1-126N positive control pep-
tide. Therefore, we used another protocol for the gen-
eration of CD8+ T lymphocyte lines where peptide-
pulsed DC2d were used to prime the CD8+ T lym-
phocytes and peptide-pulsed monocytes were used for 
subsequent T lymphocyte stimulations. To investigate 
whether the MPP11 synthetic peptides could stimulate 
peptide-specific CTLs, the generated T cell lines were 
tested against different HLA-A*0201+ targets in the 
presence or absence of autologous peptide using a chro-
Figure 1. The binding ability of mPP11-derived peptides to the Hla-a*0201 molecule as 
measured by the T2 peptide-binding assay. The wT1-187n peptide served as a positive 
control. mPP-3 and mPP-4 peptides stably bind to the Hla-a*0201. The peptides 
mPP-1n, mPP-2 and the modified peptide mPP-1Y showed no binding to Hla-a*0201 
and thereby were not used to generate CTls. each value represents the average of 
duplicate assays and error bars indicate the SD. 
Table  1. Peptide Sequences derived from the mPP11 protein and their binding 
prediction to the Hla- a*0201 molecule. 
    Given name Start position Sequence SYFPEITHI Score
   mPP-1n 421 QlliKavnl 25
   mPP-1Y Y-422 YlliKavnl 27
   mPP-2 419 DlQlliKav 24
   mPP-3 13 aimlllPSa 23
   mPP-4 37 STlCQvePv 22
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mium release assay and an ELISPOT assay after 3 to 8 
rounds of stimulations. 
Cytotoxic T cell lines generated against MPP-4 
(STLCQVEPV) peptide produced specific IFN-γ
After the third round of stimulation, the specificity of 
in vitro primed CTLs was first tested for specific IFN-γ 
release by stimulation with the corresponding peptides 
using an ELISPOT assay. The CTLs generated against 
the MPP-4 (STLCQVEPV) peptide produced specific 
IFN-γ  spots when stimulated with T2-loaded peptide 
whereas non-specific production was seen in case of 
CTLs generated against the MPP-3 (AIMLLLPSA) 
peptide as shown in Figure 2A and B. 
Because CD8+ T lymphocytes are known to use 
cytotoxic factors such as granzyme B and/or perforin 
to induce killing of their target cells, so we tested the 
MPP-4- CTL for the release of granzyme B and/or 
perforin after 5 rounds of stimulation. MPP-4 pulsed 
T2 or autologous LCLs were used as stimulators. 
There was no specific production of granzyme B and/
or perforin to the peptide MPP-4 due to very high 
background responses seen when T lymphocytes were 
used alone in the assay (Figures 2c and 2d). 
T lymphocytes generated against the MPP-4 peptide 
specifically lyse MPP-4-pulsed target cells and leuke-
mic cells 
The expanded MPP11 T lymphocyte lines gener-
ated against the MPP-4 and MPP-3 peptides were 
tested for their specific cytotoxicity against T2 cells 
and autologous LCLs using a chromium release assay. 
Specific lysis of 17.8% against the T2 cells loaded with 
the MPP-4 peptide compared to 0% in the absence of 
peptide was recorded for TCL21 MPP-4 at effector 
to target ratio (E:T) of 50:1 (Figure 3A). In addition, 
35% specific lysis for the same T lymphocytes line 
was recorded against autologous LCL loaded with the 
MPP-4 peptide compared to 6% against autologous 
LCL in the absence of the peptide at E: T ratio of 50:1 
(Figure 3b). 
The cytotoxic activity of the MPP-4 T lympho-
cytes line against the leukemic K562-A2.1 cell line 
was also measured (K562-A2.1 cells which naturally 
express the MPP11 antigen was transfected with the 
HLA-A*0201 molecule). Interestingly, the MPP-4 
CTLs exerted a lytic activity of 14% against this leu-
kemia cell line at an E:T ratio of 50:1, whereas only 
7% lysis towards the wild type K-562 (lacking the 
Figure 2. Specificity of CTls generated against the mPP-3 and mPP-4 peptides using an eliSPOT assay. The CTl lines were 
established from bC-21, an Hla-a0201+ donor, following three to five rounds of in vitro T lymphocyte stimulations. mPP-4-CTls 
releases specific iFn-g upon re-stimulation with T2 cells pulsed with mPP-4 peptide (a). CTls generated against the mPP-3 peptide 
did not release specific iFn-g (b). High and non-specific granzyme b (C) and perforin secretion by CTl-mPP-4 (D). all assays were 
performed in triplicate and error bars indicate the SD. 
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HLA-A2 expression) was recorded at the same E:T 
ratio (Figure 3c). Similar to the ELISPOT results, 
the T lymphocytes line generated against the MPP-
3 peptide did not show any specific cytotoxic activity 
(Figure 3d). 
DIsCussIOn 
CD8+ CTLs recognize endogenously processed 
peptides3,30 consisting of 8-11 amino acids, most 
commonly 9 amino acids long, presented on the cell 
surface of target cells in the context of major MHC 
class I molecules. These cells are believed to play an 
important role in identifying and eliminating tumor 
cells.31 To date, several CD8+ CTL epitopes derived 
from leukemia antigens have been identified, and some 
of them have been investigated in clinical trials.32-34 
Importantly, the graft-versus-leukemia (GVL) effect 
often seen after allogeneic hematopoietic stem cell 
transplantation (AHSCT) has been found to be me-
diated mostly by donor-derived CD8+ T lymphocytes 
recognizing peptides derived from leukemia antigens 
and/or minor histocompatibilty antigens (mHAs) 
presented on recipient cells.35-37 Overexpressed anti-
gens such as WT1, PR-3 and MUC1 represent pos-
sible targets of specific GVL reactions.38-40 
Previous studies have reported the existence of a 
humoral response against the MPP11 protein as well 
as the overexpression of this protein in patients with 
myeloid leukemias.15-17 However, the identification of 
CD8+ CTL epitopes derived from this protein is a 
crucial contribution to the field of leukemia immuno-
therapy. In this study, we investigated potential CD8+ 
CTL epitopes derived from the MPP11 antigen us-
ing a reverse immunology approach.41 The reverse im-
munology approach permits the identification of class 
I as well as class II candidate epitopes derived from 
known tumor antigens on the basis of HLA-bind-
ing motifs.42,43 Using this approach, numerous epit-
opes were identified in leukemia21,29,44,45 as well as in 
solid tumours.46-51 We first examined the amino acid 
Figure 3. Cytotoxic activity of mPP11 CTl lines generated from the bC-21 donor as tested using a standard chromium release assay. 
mPP11-CTl lines were challenged with different Hla-a0201+ target cells at different e: T ratios. T2 and autologous lCls were pulsed 
with each peptide before challenge. mPP-4 specific cytotoxic T cells specifically lysed peptide loaded T2 cells (a) and autologous lCl 
pulsed peptide (b). The same CTl lines lysed the leukemic cell line K-562-a2.1 and K-562 by TCl21 mPP-4 (C). non-specific lysis of CTl 
line generated against mPP-3 (D). 
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sequences derived from the MPP11 protein for the 
presence of peptides containing binding motifs for 
one of the most frequent A*0201 class I alleles,52 us-
ing a computer-based epitope prediction program. We 
identified four MPP11-derived peptides predicted to 
bind with high affinity to the HLA-A*0201 molecule. 
The peptides were named MPP-1N, MPP-2, MPP-3 
and MPP-4. Using the T2 binding assay, we tested the 
actual binding capacity of the selected peptides. The 
MPP11-derived peptides MPP-3 and MPP-4 record-
ed binding scores lower than MPP-1N, and MPP2 
scores as determined by the SYFPEITHI software. 
However, in the actual T2 binding assay, MPP-3 and 
MPP-4 were found to have higher binding affinities 
compared to the two other peptides. This is probably 
due to a very poor dissolution of the MPP-1N and 
MPP-2 peptides since more hydrophobic amino acids 
are contained within their sequence. In addition to the 
four predicted peptides, we modified the amino acid 
sequence of the highest scoring peptide i.e., MPP-1N 
(QLLIKAVNL). We20 and others53,54 have shown that 
introducing a tyrosine amino acid residue at the first 
position (P1Y) of a peptide enhances epitope immu-
nogenicity. Therefore, a tyrosine amino acid residue was 
introduced in P1 of the MPP-1N peptide to boost its 
binding affinity and/or immunogenicity. The modifica-
tion of MPP-1N peptide enhanced the binding affinity 
of the modified MPP-1Y peptide using the algorithm 
prediction but in the actual binding assay, the analogue 
peptide could not stabilize the HLA-A*0201 molecule 
which is again may be due to its poor dissolution. 
Consistent with other groups21,26,29 who have suc-
ceeded in identifying CD8+ CTL epitopes using a 
simple method that employs T2 cells as antigen-pre-
senting cells, we could not generate specific immune 
responses using this method to both MPP11-derived 
peptides as well as WT1-126N peptide which was in-
cluded as a positive control. Since MPP11 and WT1 
are self proteins, the majority of high avidity CD8+ 
T lymphocytes may have been deleted during thymic 
maturation.55 Thus it is more difficult to generate CTL 
responses from the remaining low avidity-naïve precur-
sors because their activation requires more stringent co-
stimulatory requirements.56,57 Therefore, we used DCs 
as antigen-presenting cells for the generation of anti-
MPP11 CTL responses. DCs are known as the profes-
sional antigen presenting cells because of their unique 
ability to stimulate naïve T lymphocyte responses. The 
conventional protocol for generating monocyte-derived 
DCs included 7-9 days of culture, however, Dauer et 
al,24 described a rapid protocol for the generation of 
mature DCs from monocytes within only two days of 
in vitro culture. Such cells, termed fast DC or DC2d, 
were found to be capable of inducing tumor-specific 
CD8+ CTL responses as effectively as DCs gener-
ated according to the conventional 7-day protocol.25,58 
Moreover, CTL lines primed with the DC2d cells ex-
panded more effectively and showed greater lytic activ-
ity than lines stimulated with the DC7d cells.25,58 Using 
the DC2d protocol, we were able to detect antigen-spe-
cific responses by the CTL-21 line generated against the 
MPP-4 peptide. MPP-4-CTLs selectively recognized 
peptide-loaded T2 cells and specifically responded to 
the targets by releasing IFN-g in an ELISPOT assay. 
Importantly, these T lymphocytes specifically killed 
T2 cells and autologous LCLs when loaded with the 
MPP-4 peptide. Moreover, they were capable of rec-
ognizing the leukemia cell line K562-A2.1 expressing 
the MPP11 protein. Even though T2 cells were not ef-
ficient at priming and generating specific-CD8+ CTL 
immunity, these cells were very useful as targets when 
conducting functional assays such as cytotoxicity and 
ELISPOT assays. 
We have attempted to generate MPP-4-specific 
CTLs from four healthy HLA-A*0201 positive indi-
viduals; however, specific responses could only be ob-
served in one CTL line established from one donor 
(BC-21). The failure to obtain specific CTL responses 
to tumor antigens in all donors tested was observed 
in a previous study was thought to be due to the low 
frequency of peptide-specific CD8+ T lymphocyte 
precursors in healthy individuals.59 We aimed to clone 
the MPP-4 CTL line before testing its capability of 
recognizing fresh A*0201-positive leukemic cells that 
overexpress the MPP11 protein. Unfortunately, regard-
less of our attempts to generate MPP-4-specific clones, 
we could not generate any specific clones. Standard 
techniques for cloning T cells employ stimulation with 
antigen loaded-APCs in the presence of IL-2 and allo-
geneic feeder cells in limiting dilution cultures followed 
by repeated re-stimulations to maintain growth and 
specificity. In the first attempt, the MPP-4 CTL line 
was cloned by stimulation with peptide pulsed-T2 cells 
in the presence of allogeneic feeder cells in the pres-
ence of IL-2, IL-15 and OKT3. IL-2 is the cytokine 
frequently used to promote the survival and expansion 
of cultured T cells.60 IL-2 and IL-15 share the b-chain 
and the common γ-chain receptor (IL-2/IL-15 Rbγc), 
but each cytokine has its unique a-chain receptor.61,62 
IL-15 was initially identified by its capability to pro-
mote the development of NK cells and the survival of 
CD8+ memory T lymphocytes in vivo.63-65 However, it 
has been reported that antitumor-CTLs expanded and 
survived for relatively long time periods in vitro in the 
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presence of IL-15 whereas CTLs maintained in IL-2 
died at earlier stages.66 Furthermore, IL-15-maintained 
CTLs retained their effector function as CTLs and did 
not switch into memory cells.66 For TCR triggering, we 
used OKT3 as reported previously.25 Because all of the 
generated clones were not specific, we conducted anoth-
er attempt to clone the line but without the addition of 
either IL-15 or OKT3 antibody. The generated T lym-
phocytes clones were very few and died at early stage 
perhaps as a result of an old T lymphocyte culture. 
In summary, our data suggests that CD8+ CTL reac-
tive to the MPP-4 peptide could be generated from the 
T lymphocytes repertoire of HLA-A*0201+ healthy 
individuals. More importantly, these CTLs were able to 
specifically lyse the K562-A2.1 leukemic cells naturally 
expressing the MPP11 antigen. 
Acknowledgments
We are very grateful to the administration of the Research 
Centre and the Research Advisory Council (RAC) for 
their support. This work was sponsored by RAC (proposal 
# 2040010). We would like to thank Dr. Wolfgang Herr 
(University of Mainz, Germany) for providing the K-562 
cells transfected with the HLA-A*0201 gene. 
1. bozzone Dm. leukemia. 1st ed: Chelsea House, 
new York. 2009. 
2. leukemia Facts and Statistics. leukemia and 
lymphoma Society, 2009. 
3. Tallman mS, gilliland Dg, rowe Jm. Drug 
therapy for acute myeloid leukemia. blood. 
2005;106:1154-1163. 
4. guglielmelli P, Zini r, bogani C, et al. molecular 
profiling of CD34+ cells in idiopathic myelofibrosis 
identifies a set of disease-associated genes and 
reveals the clinical significance of wilms’ tumor 
gene 1 (wT1). Stem Cells. 2007;25:165-173. 
5. boon T, Old lJ. Cancer Tumor antigens. Curr 
Opin immunol. 1997;9:681-683. 
6. Dermime S, armstrong a, Hawkins re, Stern Pl. 
Cancer vaccines and immunotherapy. br med bull 
2002;62:149-162. 
7. Dermime S, gilham De, Shaw Dm, et al. vaccine 
and antibody-directed T cell tumour immunothera-
py. biochim biophys acta. 2004;1704:11-35. 
8. matsumoto-Taniura n, Pirollet F, monroe r, 
gerace l, westendorf Jm. identification of novel 
m phase phosphoproteins by expression cloning. 
mol biol Cell. 1996;7:1455-1469. 
9. Davis Fm, Tsao TY, Fowler SK, rao Pn. mono-
clonal antibodies to mitotic cells. Proc natl acad 
Sci USa. 1983;80:2926-2930. 
10. Zenklusen JC, Conti CJ. Cytogenetic, molecular 
and functional evidence for novel tumor suppres-
sor genes on the long arm of human chromosome 
7. mol Carcinog. 1996;15:167-175. 
11. Hundley Ha, walter w, bairstow S, Craig 
ea. Human mpp11 J protein: ribosome-tethered 
molecular chaperones are ubiquitous. Science. 
2005;308:1032-1034. 
12. Otto H, Conz C, maier P, et al. The chaperones 
mPP11 and Hsp70l1 form the mammalian ribo-
some-associated complex. Proc natl acad Sci 
USa. 2005;102:10064-10069. 
13. resto va, Caballero Ol, buta mr, et al. a puta-
tive oncogenic role for mPP11 in head and neck 
squamous cell cancer. Cancer res. 2000;60:5529-
5535. 
14. gure aO, Stockert e, Scanlan mJ, et al. Se-
rological identification of embryonic neural pro-
teins as highly immunogenic tumor antigens in 
small cell lung cancer. Proc natl acad Sci USa. 
2000;97:4198-4203. 
15. greiner J, ringhoffer m, Taniguchi m, et al. 
Characterization of several leukemia-associated 
antigens inducing humoral immune responses in 
acute and chronic myeloid leukemia. int J Cancer. 
2003;106:224-231. 
16. Schmitt m, li l, giannopoulos K, et al. Chronic 
myeloid leukemia cells express tumor-associated 
antigens eliciting specific CD8+ T-cell responses 
and are lacking costimulatory molecules. exp He-
matol. 2006;34:1709-1719. 
17. greiner J, ringhoffer m, Taniguchi m, et al. 
mrna expression of leukemia-associated anti-
gens in patients with acute myeloid leukemia for 
the development of specific immunotherapies. int 
J Cancer. 2004;108:704-711. 
18. van der geld Ym, limburg PC, Kallenberg Cg. 
Proteinase 3, wegener’s autoantigen: from gene 
to antigen. J leukoc biol 2001;69:177-190. 
19. rammensee H, bachmann J, emmerich nP, 
bachor Oa, Stevanovic S. SYFPeiTHi: database 
for mHC ligands and peptide motifs. immunogen-
et. 1999;50:213-219. 
20. al Qudaihi g, lehe C, negash m, et al. en-
hancement of lytic activity of leukemic cells by 
CD8+ cytotoxic T lymphocytes generated against 
a wT1 peptide analogue. leuk lymphoma. 
2009;50:260-269. 
21. molldrem J, Dermime S, Parker K, et al. Tar-
geted T-cell therapy for human leukemia: cytotoxic 
T lymphocytes specific for a peptide derived from 
proteinase 3 preferentially lyse human myeloid 
leukemia cells. blood. 1996;88:2450-2457. 
22. britten Cm, meyer rg, Kreer T, Drexler i, wol-
fel T, Herr w. The use of Hla-a*0201-transfected 
K562 as standard antigen-presenting cells for 
CD8(+) T lymphocytes in iFn-gamma eliSPOT as-
says. J immunol methods. 2002;259:95-110. 
23. neitzel H. a routine method for the establish-
ment of permanent growing lymphoblastoid cell 
lines. Hum genet. 1986;73:320-326. 
24. Dauer m, Obermaier b, Herten J, et al. mature 
dendritic cells derived from human monocytes 
within 48 hours: a novel strategy for dendritic cell 
differentiation from blood precursors. J immunol. 
2003;170:4069-4076. 
25. Ho wY, nguyen Hn, wolfl m, Kuball J, green-
berg PD. in vitro methods for generating CD8+ 
T-cell clones for immunotherapy from the naive 
repertoire. J immunol methods. 2006;310:40-52. 
26. Houbiers Jg, nijman Hw, van der burg SH, et 
al. in vitro induction of human cytotoxic T lympho-
cyte responses against peptides of mutant and 
wild-type p53. eur J immunol. 1993;23:2072-2077. 
27. Dermime S, bertazzoli C, marchesi e, et al. 
lack of T-cell-mediated recognition of the fusion 
region of the pml/rar-alpha hybrid protein by 
lymphocytes of acute promyelocytic leukemia pa-
tients. Clin Cancer res. 1996;2:593-600. 
28. Clark wH, Jr., elder De, guerry Dt, et al. 
model predicting survival in stage i melanoma 
based on tumor progression. J natl Cancer inst. 
1989;81:1893-1904. 
29. Oka Y, elisseeva Oa, Tsuboi a, et al. Human 
cytotoxic T-lymphocyte responses specific for 
peptides of the wild-type wilms’ tumor gene (wT1 
) product. immunogenet. 2000;51:99-107. 
30. Tallman mS. new strategies for the treatment 
of acute myeloid leukemia including antibodies 
and other novel agents. Hematology am Soc He-
matol educ Program. 2005:143-150. 
31. melief CJ, Kast wm. T-cell immunotherapy of 
tumors by adoptive transfer of cytotoxic T lympho-
cytes and by vaccination with minimal essential 
epitopes. immunol rev. 1995;145:167-177. 
32. Heslop He, Stevenson FK, molldrem JJ. immu-
notherapy of hematologic malignancy. Hematol-
ogy am Soc Hematol educ Program. 2003:331-349. 
33. Qazilbash mH, wieder e, rios r, et al. vacci-
nation with the Pr1 leukemia-associated antigen 
Can induce Complete remission in Patients with 
myeloid leukemia. aSH annual meeting ab-
stracts 2004;104:259. 
34. Schmitt m, Schmitt a, rojewski mT, et al. 
rHamm-r3 peptide vaccination in patients with 
acute myeloid leukemia, myelodysplastic syn-
drome, and multiple myeloma elicits immunologic 
and clinical responses. blood. 2008;111:1357-1365. 
35. Schetelig J, Kiani a, Schmitz m, ehninger g, 
bornhauser m. T cell-mediated graft-versus-
leukemia reactions after allogeneic stem cell 
transplantation. Cancer immunol immunother. 
2005;54:1043-1058. 
36. wu CJ, ritz J. induction of tumor immunity fol-
lowing allogeneic stem cell transplantation. adv 
immunol. 2006;90:133-173. 
37. appelbaum Fr. Haematopoietic cell transplan-
tation as immunotherapy. nature. 2001;411:385-
389. 
38. Kapp m, Stevanovic S, Fick K, et al. CD8+ T-cell 
responses to tumor-associated antigens correlate 
with superior relapse-free survival after allo-SCT. 
bone marrow Transpl. 2009;43:399-410. 
39. molldrem JJ, lee PP, wang C, et al. evidence 
that specific T lymphocytes may participate in the 
elimination of chronic myelogenous leukemia. nat 
med. 2000;6:1018-1023. 
40. rezvani K, grube m, brenchley Jm, et al. 
Functional leukemia-associated antigen-specific 
memory CD8+ T cells exist in healthy individuals 
and in patients with chronic myelogenous leuke-
mia before and after stem cell transplantation. 
blood. 2003;102:2892-2900. 
41. viatte S, alves Pm, romero P. reverse im-
munology approach for the identification of CD8 
REfEREnCEs
original research reportnOvel PePTiDe reCOgniZeD bY CD8+ CTl
Hematol Oncol Stem Cell Ther 3(1)     First Quarter 2010 hemoncstem.edmgr.com 33
T-cell-defined antigens: advantages and hurdles. 
immunol Cell biol. 2006;84:318-330. 
42. Stevanovic S. identification of tumour-associ-
ated T-cell epitopes for vaccine development. nat 
rev Cancer. 2002;2:514-520. 
43. Paschen a, eichmuller S, Schadendorf D. iden-
tification of tumor antigens and T-cell epitopes, 
and its clinical application. Cancer immunol im-
munother. 2004;53:196-203. 
44. greiner J, li l, ringhoffer m, et al. identification 
and characterization of epitopes of the receptor 
for hyaluronic acid-mediated motility (rHamm/
CD168) recognized by CD8+ T cells of Hla-a2-pos-
itive patients with acute myeloid leukemia. blood. 
2005;106:938-945. 
45. asemissen am, Keilholz U, Tenzer S, et al. 
identification of a highly immunogenic Hla-a*01-
binding T cell epitope of wT1. Clin Cancer res. 
2006;12:7476-7482. 
46. alves Pm, Faure O, graff-Dubois S, et al. epha2 
as target of anticancer immunotherapy: identifica-
tion of Hla-a*0201-restricted epitopes. Cancer 
res. 2003;63:8476-8480. 
47. ayyoub m, Stevanovic S, Sahin U, et al. Pro-
teasome-assisted identification of a SSX-2-de-
rived epitope recognized by tumor-reactive CTl 
infiltrating metastatic melanoma. J immunol. 
2002;168:1717-1722. 
48. Fujie T, Tahara K, Tanaka F, mori m, Takesako K, 
akiyoshi T. a mage-1-encoded Hla-a24-binding 
synthetic peptide induces specific anti-tumor cyto-
toxic T lymphocytes. int J Cancer. 1999;80:169-172. 
49. Kawashima i, Hudson SJ, Tsai v, et al. The multi-
epitope approach for immunotherapy for cancer: 
identification of several CTl epitopes from various 
tumor-associated antigens expressed on solid epi-
thelial tumors. Hum immunol. 1998;59:1-14. 
50. Kessler JH, beekman nJ, bres-vloemans Sa, 
et al. efficient identification of novel Hla-a(*)0201-
presented cytotoxic T lymphocyte epitopes in the 
widely expressed tumor antigen Prame by pro-
teasome-mediated digestion analysis. J exp med. 
2001;193:73-88. 
51. neumann F, wagner C, Preuss KD, et al. identi-
fication of an epitope derived from the cancer tes-
tis antigen HOm-TeS-14/SCP1 and presented by 
dendritic cells to circulating CD4+ T cells. blood. 
2005;106:3105-3113. 
52. Player ma, barracchini KC, Simonis Tb, et al. 
Differences in frequency distribution of Hla-a2 
subtypes between north american and italian 
white melanoma patients: relevance for epitope 
specific vaccination protocols. J immunother em-
phasis Tumor immunol. 1996;19:357-363. 
53. Tourdot S, Scardino a, Saloustrou e, et al. a 
general strategy to enhance immunogenicity of 
low-affinity Hla-a2. 1-associated peptides: impli-
cation in the identification of cryptic tumor epit-
opes. eur J immunol. 2000;30:3411-3421. 
54. valmori D, Fonteneau JF, lizana Cm, et al. 
enhanced generation of specific tumor-reactive 
CTl in vitro by selected melan-a/marT-1 im-
munodominant peptide analogues. J immunol. 
1998;160:1750-1758. 
55. Starr TK, Jameson SC, Hogquist Ka. Positive 
and negative selection of T cells. annu rev im-
munol. 2003;21:139-176. 
56. Janeway Ca, Jr., bottomly K. Signals and signs 
for lymphocyte responses. Cell 1994;76:275-285. 
57. Swain Sl, Croft m, Dubey C, et al. From naive 
to memory T cells. immunol rev. 1996;150:143-
167. 
58. Dauer m, Schad K, Herten J, et al. FastDC 
derived from human monocytes within 48 h ef-
fectively prime tumor antigen-specific cytotoxic T 
cells. J immunol methods. 2005;302:145-155. 
59. Ohminami H, Yasukawa m, Fujita S. Hla class 
i-restricted lysis of leukemia cells by a CD8(+) 
cytotoxic T-lymphocyte clone specific for wT1 
peptide. blood. 2000;95:286-293. 
60. Smith Ka. interleukin-2: inception, impact, and 
implications. Science 1988;240:1169-1176. 
61. Carson we, giri Jg, lindemann mJ, et al. in-
terleukin (il) 15 is a novel cytokine that activates 
human natural killer cells via components of the 
il-2 receptor. J exp med. 1994;180:1395-1403. 
62. grabstein KH, eisenman J, Shanebeck K, et 
al. Cloning of a T cell growth factor that interacts 
with the beta chain of the interleukin-2 receptor. 
Science. 1994;264:965-968. 
63. Colucci F, Caligiuri ma, Di Santo JP. what 
does it take to make a natural killer? nat rev im-
munol. 2003;3:413-425. 
64. Zhang X, Sun S, Hwang i, Tough DF, Sprent 
J. Potent and selective stimulation of memory-
phenotype CD8+ T cells in vivo by il-15. immun. 
1998;8:591-599. 
65. Schluns KS, lefrancois l. Cytokine control of 
memory T-cell development and survival. nat rev 
immunol. 2003;3:269-279. 
66. lu J, giuntoli rl, 2nd, Omiya r, Kobayashi H, 
Kennedy r, Celis e. interleukin 15 promotes anti-
gen-independent in vitro expansion and long-term 
survival of antitumor cytotoxic T lymphocytes. Clin 
Cancer res. 2002;8:3877-3884.
